Literature DB >> 17023127

Characterisation and physical stability of PEGylated glucagon.

Pernille Stigsnaes1, Sven Frokjaer, Simon Bjerregaard, Marco van de Weert, Peter Kingshott, E Horn Moeller.   

Abstract

Glucagon was mono-PEGylated with PEG 5000 at Lys-12 to examine the effect on conformation and physical stability during purification and freeze-drying. The model peptide glucagon is highly unstable and readily forms fibrils in solution. Secondary structure was determined by FTIR and far-UV CD and physical stability was assessed by the Thioflavin T assay. Glucagon samples were included, which underwent the same RP-HPLC purification and/or freeze-drying as glucagon-PEG 5000. After purification and freeze-drying glucagon samples showed formation of intermolecular beta-sheet by FTIR, this correlated with shorter lag-times for fibrillation in the Thioflavin T assay. Formation of intermolecular beta-sheet was less apparent for glucagon-PEG 5000 and no fibrillation was detected by Thioflavin T assay. Apparently PEGylation significantly improved the physical stability of glucagon after purification and freeze-drying, possibly by steric hindrance of peptide-peptide interactions. Alterations in the secondary structure were observed for freeze-dried and reconstituted peptide samples by liquid FTIR. The peak for alpha-helix shifted to 1664 cm(-1), which could possibly be explained by formation of 3(10)-helix. Neither 3(10)-helix nor intermolecular beta-sheet could be detected by far-UV CD, where all peptide samples showed similar spectra. In conclusion, glucagon-PEG 5000 showed a significantly improved physical stability during purification and freeze-drying compared to glucagon.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023127     DOI: 10.1016/j.ijpharm.2006.09.002

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

1.  Direct quantitative analysis of a 20 kDa PEGylated human calcitonin gene peptide antagonist in cynomolgus monkey serum using in-source CID and UPLC-MS/MS.

Authors:  Hongyan Li; Mark J Rose; Jerry Ryan Holder; Marie Wright; Les P Miranda; Christopher A James
Journal:  J Am Soc Mass Spectrom       Date:  2011-06-23       Impact factor: 3.109

2.  Early stages of amyloid fibril formation studied by liquid-state NMR: the peptide hormone glucagon.

Authors:  Anna Sigrid Pii Svane; Kasper Jahn; Taru Deva; Anders Malmendal; Daniel Erik Otzen; Jens Dittmer; Niels Chr Nielsen
Journal:  Biophys J       Date:  2008-03-13       Impact factor: 4.033

3.  Conformational and aggregation properties of a PEGylated alanine-rich polypeptide.

Authors:  Ayben Top; Christopher J Roberts; Kristi L Kiick
Journal:  Biomacromolecules       Date:  2011-05-09       Impact factor: 6.988

4.  Structural transitions and interactions in the early stages of human glucagon amyloid fibrillation.

Authors:  Balakrishnan S Moorthy; Hamed Tabatabaei Ghomi; Markus A Lill; Elizabeth M Topp
Journal:  Biophys J       Date:  2015-02-17       Impact factor: 4.033

5.  Prevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation.

Authors:  José A Rodríguez-Martínez; Izarys Rivera-Rivera; Kai Griebenow
Journal:  J Pharm Pharmacol       Date:  2011-05-03       Impact factor: 3.765

6.  Multimeric peptide-based PEG nanocarriers with programmable elimination properties.

Authors:  Simi Gunaseelan; Shahriar Pooyan; Peiming Chen; Mahta Samizadeh; Matthew S Palombo; Stanley Stein; Xiaoping Zhang; Patrick J Sinko
Journal:  Biomaterials       Date:  2009-07-31       Impact factor: 12.479

7.  Toward top-down determination of PEGylation site using MALDI in-source decay MS analysis.

Authors:  Chul Yoo; Detlev Suckau; Volker Sauerland; Michael Ronk; Minhui Ma
Journal:  J Am Soc Mass Spectrom       Date:  2008-11-01       Impact factor: 3.109

Review 8.  Chemical Glycosylation and Its Application to Glucose Homeostasis-Regulating Peptides.

Authors:  Chaitra Chandrashekar; Mohammed Akhter Hossain; John D Wade
Journal:  Front Chem       Date:  2021-04-12       Impact factor: 5.221

9.  Preferential Interactions and the Effect of Protein PEGylation.

Authors:  Louise Stenstrup Holm; Peter W Thulstrup; Marina R Kasimova; Marco van de Weert
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

10.  Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery.

Authors:  Md Abdur Rashid; Amged Awad Elgied; Yahya Alhamhoom; Enoch Chan; Llew Rintoul; Ayman Allahham; Nazrul Islam
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.